The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Hayes' Principles and Methods of Toxicology
Abstract
Hayes' Principles and Methods of Toxicology has long been established as a reliable reference to the concepts, methodologies, and assessments integral to toxicology. The new sixth edition has been revised and updated while maintaining the same high standards that have made this volume a benchmark resource in the field. With new authors and new chap
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Artursson, P., Palm, K., & Luthman, K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00128-9 · Cited by 1,543
Cell Proliferation in Carcinogenesis
Cohen, S. M., & Ellwein, L. B. (1990) · Science · doi:10.1126/science.2204108 · Cited by 1,050
Expression in Escherichia coli of chemically synthesized genes for human insulin.
Goeddel, D. V., Kleid, D. G., Bolivar, F., Heyneker, H. L., Yansura, D. G., Crea, R., Hirose, T., Kraszewski, A., Itakura, K., & Riggs, A. D. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.1.106 · Cited by 869
Too Many Rodent Carcinogens: Mitogenesis Increases Mutagenesis
Ames, B. N., & Gold, L. S. (1990) · Science · doi:10.1126/science.2136249 · Cited by 770
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
Toxicology rethinks its central belief
Calabrese, E. J., & Baldwin, L. A. (2003) · Nature · doi:10.1038/421691a · Cited by 719
Calabrese, E. J. (2005) · Environmental Pollution · doi:10.1016/j.envpol.2004.10.001 · Cited by 543
LUSTER, M. (1988) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(88)90247-3 · Cited by 522
Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation
Larsson, H., Carlsson, E., Mattsson, H., Lundell, L., Sundler, F., Sundell, G., Wallmark, B., Watanabe, T., & Håkanson, R. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90938-8 · Cited by 511
Synthesis in E. coli of a polypeptide with human leukocyte interferon activity
Nagata, S., Taira, H., Hall, A., Johnsrud, L., Streuli, M., Ecsödi, J., Boll, W., Cantell, K., & Weissmann, C. (1980) · Nature · doi:10.1038/284316a0 · Cited by 481
Human Growth Hormone: Complementary DNA Cloning and Expression in Bacteria
Martial, J. A., Hallewell, R. A., Baxter, J. D., & Goodman, H. M. (1979) · Science · doi:10.1126/science.377496 · Cited by 401
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
Drug Metabolites in Safety Testing
Baillie, T. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9440 · Cited by 371
Texicological studies on omeprazole
L, E., E, H., N, H., E, C., & C, L. (1985) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528509095819 · Cited by 354
Preclinical safety evaluation of biotechnology-derived pharmaceuticals
Cavagnaro, J. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd822 · Cited by 340
In silico toxicology for the pharmaceutical sciences☆
Valerio Jr., L. G. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.08.022 · Cited by 296
The future of drug safety testing: expanding the view and narrowing the focus
Stevens, J. L., & Baker, T. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.009 · Cited by 286
Ito, K., & Houston, J. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9015-1 · Cited by 260
Recognition of Adverse and Nonadverse Effects in Toxicity Studies
Lewis, R. W., Billington, R., Debryune, E., Gamer, A., Lang, B., & Carpanini, F. (2002) · Toxicologic Pathology · doi:10.1080/01926230252824725 · Cited by 246
The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)
Dorato, M. A., & Engelhardt, J. A. (2005) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2005.05.004 · Cited by 245
Frothingham, R. (2001) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.20.1468.34482 · Cited by 208
Hormesis as a biological hypothesis.
Calabrese, E. J., & Baldwin, L. A. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106s1357 · Cited by 202
Dust overloading of the lungs: Update and appraisal
Morrow, P. E. (1992) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(92)90002-a · Cited by 198
Filipsson, A. F., Sand, S., Nilsson, J., & Victorin, K. (2003) · Critical Reviews in Toxicology · doi:10.1080/10408440390242360 · Cited by 197
Wharf, C., & London, E. (2013) · Cited by 189
Evaluating the Human Relevance of Chemically Induced Animal Tumors
Cohen, S. M. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh073 · Cited by 163
Caldwell, G. W., Masucci, J. A., Yan, Z., & Hageman, W. (2004) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190588 · Cited by 148
Schein, P. S., Davis, R. D., Carter, S., Newman, J., Schein, D. R., & Rall, D. P. (1970) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt19701113 · Cited by 146
Histopathologic Approaches to Detect Changes Indicative of Immunotoxicity
Kuper, C. F., Harleman, J. H., Richter-Reichelm, H. B., & Vos, J. G. (2000) · Toxicologic Pathology · doi:10.1177/019262330002800317 · Cited by 140
SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING
Smith, D. A., & Obach, R. S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005041 · Cited by 138
Human Carcinogenic Risk Evaluation: An Alternative Approach to the Two-Year Rodent Bioassay
Cohen, S. M. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh159 · Cited by 132
Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens
Tennant, R. W., Spalding, J. W., & French, J. E. (1996) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/s0165-1110(96)90016-0 · Cited by 130
Carlsson, E. I., Larsson, H., Mattsson, H., Ryberg, B., & Sundell, G. (1986) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528609090884 · Cited by 126
Carcinogenicity Testing and the Evaluation of Regulatory Requirements for Pharmaceuticals
Contrera, J. F., Jacobs, A. C., & DeGeorge, J. J. (1997) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1997.1085 · Cited by 125
Regulatory considerations for preclinical development of anticancer drugs
DeGeorge, J. J., Ahn, C., Andrews, P. A., et al. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050726 · Cited by 124
Issues in Pharmaceutical Economics
Steele, H., & Chien, R. I. (1980) · Southern Economic Journal · doi:10.2307/1057285 · Cited by 120
Toxicity of interferon and interleukin
Fent, K., & Zbinden, G. (1987) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(87)90083-6 · Cited by 112
Pharmaceutical Excipient Development: The Need for Preclinical Guidance
Baldrick, P. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1421 · Cited by 112
AYERS, K. M. (1996) · Fundamental and Applied Toxicology · doi:10.1006/faat.1996.0118 · Cited by 105
Preclinical development of monoclonal antibodies: Considerations for the use of non-human primates
Chapman, K. L., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovic, J. J., Baldrick, P., Buckley, L. A., Jacobs, A., Hale, G., et al. (2009) · mAbs · doi:10.4161/mabs.1.5.9676 · Cited by 104
Nagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
MacDonald, J. S. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfh037 · Cited by 93
The Utility of Two Rodent Species in Carcinogenic Risk Assessment of Pharmaceuticals in Europe
Oosterhout, J. P. J. V., van der Laan, J. W., Waal, E. J. D., Olejniczak, K., Hilgenfeld, M., Schmidt, V. C., & Bass, R. (1997) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1996.1077 · Cited by 88
Drug Safety Tests and Subsequent Clinical Experience
Fletcher, A. P. (1978) · Journal of the Royal Society of Medicine · doi:10.1177/014107687807100915 · Cited by 85
Gao, H., Deng, S., & Obach, R. S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034637 · Cited by 83
Procedures available to examine the immunotoxicity of chemicals and drugs.
Dean, J. H., Luster, M. I., Boorman, G. A., & Lauer, L. D. (1982) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06740-7 · Cited by 82
The role of earlyin vivotoxicity testing in drug discovery toxicology
Fielden, M. R., & Kolaja, K. L. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.2.107 · Cited by 81
The Current Status of Attempts to Predict Species Differences in Drug Metabolism
Caldwell, J. (1981) · Drug Metabolism Reviews · doi:10.3109/03602538108994030 · Cited by 80
Session 6: Is Hypergastrinaemia Dangerous to Man?
Creutzfeldt, W., & Lamberts, R. (1991) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529109093198 · Cited by 76
Neonatal Mouse Assay for Tumorigenicity: Alternative to the Chronic Rodent Bioassay
Flammang, T. J., Tungeln, L. S. V., Kadlubar, F. F., & Fu, P. P. (1997) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1997.1125 · Cited by 67
Toxicokinetics and Physiologically Based Toxicokinetics in Toxicology and Risk Assessment
Dixit, R., Riviere, J. E., Krishnan, K., & Andersen, M. E. (2003) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937400306479 · Cited by 65
Toxicogenomics in Drug Development
Guerreiro, N., Staedtler, F., Grenet, O., Kehren, J., & Chibout, S. (2003) · Toxicologic Pathology · doi:10.1080/01926230390224656 · Cited by 65
Forecasting Drug Effects in Man from Studies in Laboratory Animals
Litchfield, J. T. (1961) · JAMA · doi:10.1001/jama.1961.73040270021004c · Cited by 54
Halpin, R. A., Ulm, E. H., Till, A. E., Kari, P. H., Vyas, K. P., Hunninghake, D. B., & Duggan, D. E. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08192-9 · Cited by 54
Mahmood, I. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20313 · Cited by 51
“Hormesis”—An Inappropriate Extrapolation from the Specific to the Universal
Axelrod, D., Burns, K., Davis, D. L., & von Larebeke, N. (2004) · International Journal of Occupational and Environmental Health · doi:10.1179/oeh.2004.10.3.335 · Cited by 49
Zwickl, C. M. (1991) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(91)90112-h · Cited by 48
Implications of the new FDA/CDER immunotoxicology guidance for drugs
Hastings, K. L. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00061-9 · Cited by 40
Alternatives to the 2-species bioassay for the identification of potential human carcinogens
Ashby, J. (1996) · Human & Experimental Toxicology · doi:10.1177/096032719601500301 · Cited by 40
Predicting human pharmacokinetics from preclinical data.
Poggesi, I. (2004) · PubMed · Cited by 39
The role of pharmacological profiling in safety assessment
Williams, P. D. (1990) · Regulatory Toxicology and Pharmacology · doi:10.1016/s0273-2300(05)80061-3 · Cited by 39
Morford, L. L., Bowman, C., Blanset, D. L., Bøgh, I. B., Chellman, G. J., Halpern, W., Weinbauer, G. F., & Coogan, T. P. (2011) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20305 · Cited by 37
The assessment of potential for QT interval prolongation with new pharmaceuticals
Gralinski, M. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00100-3 · Cited by 36
Buckley, L. A., & Dorato, M. A. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.05.015 · Cited by 36
Considerations in chronic toxicity testing: the chemical, the dose, the design.
Munro, I. C. (1981) · PubMed · Cited by 35
Contrera, J. F., Jacobs, A. C., Prasanna, H. R., et al. (1995) · Journal of the American College of Toxicology · doi:10.3109/10915819509008676 · Cited by 32
Testing paradigm for prediction of development-limiting barriers and human drug toxicity
Sasseville, V. G., Lane, J. H., Kadambi, V. J., Bouchard, P. R., Lee, F. W., Balani, S. K., Miwa, G. T., Smith, P. F., & Alden, C. L. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.06.009 · Cited by 31
Drug Development Costs About $1.7 Billion
Mullin, R. (2003) · Chemical & Engineering News · doi:10.1021/cen-v081n050.p008a · Cited by 31
Preclinical toxicological testing and safeguards in clinical trials
Smith, A. D. (1982) · European Journal of Clinical Pharmacology · doi:10.1007/bf00606417 · Cited by 29
New Approaches to the Use of Pharmacokinetics in Toxicology and Drug Development
Campbell, D. B., & Ings, R. M. J. (1988) · Human Toxicology · doi:10.1177/096032718800700515 · Cited by 24
General pharmacology, the international regulatory environment, and harmonization of guidelines
Lumley, C. E. (1994) · Drug Development Research · doi:10.1002/ddr.430320406 · Cited by 22
A Brief History of Immunotoxicology and a Review of the Pharmaceutical Guidelines
Dean, J. H. (2004) · International Journal of Toxicology · doi:10.1080/10915810490435596 · Cited by 22
A retrospective comparison of the results of 6 and 12 month non-rodent toxicity studies.
Contrera, J. F., Aub, D., Barbehenn, E. K., et al. (1993) · PubMed · Cited by 22
Improved Method for Selection of the NOAEL
Calabrese, E. J., & Baldwin, L. A. (1994) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1994.1004 · Cited by 20
Proakis, A. G. (1994) · Drug Development Research · doi:10.1002/ddr.430320407 · Cited by 20
Risks, Regulation, and Rewards in New Drug Development in the United States
DiMasi, J. A. (1994) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1994.1021 · Cited by 17
The Principles of ICH S 6 and the Case‐by‐Case Approach
Cavagnaro, J. A. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse162 · Cited by 15
Parkinson, C. (1995) · Fundamental and Applied Toxicology · doi:10.1006/faat.1995.1045 · Cited by 14
FDA Recommendations for Preclinical Testing of Gonadotropin Releasing Hormone (GnRH) Analogues
Raheja, K. L., & Jordan, A. W. (1994) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1994.1015 · Cited by 11
Parkinson, C., Thomas, K. E., & Lumley, C. E. (1997) · Human & Experimental Toxicology · doi:10.1177/096032719701600501 · Cited by 10
Pharmacology and Toxicology of Novel Drug Delivery Systems
Weissinger, J. (1990) · Drug Safety · doi:10.2165/00002018-199000051-00017 · Cited by 7
Toxicological Evaluation of Biotechnology Products: A Regulatory Viewpoint
Bass, R., & Scheibner, E. (1987) · Springer eBooks · doi:10.1007/978-3-642-72558-6_29 · Cited by 7
Improvement of Predictability of Subchronic and Chronic Toxicity Studies
Zbinden, P. (1989) · The Journal of Toxicological Sciences · doi:10.2131/jts.14.supplementiii_3 · Cited by 5
Klegerman, M. E., & Plotnikoff, N. P. (1993) · Springer eBooks · doi:10.1007/978-94-015-8135-6_3 · Cited by 4
Predicting human drug safety from animal studies: Current issues.
Lasagna, L. C. (1987) · The Journal of Toxicological Sciences · doi:10.2131/jts.12.439 · Cited by 4
Cited by
Formation and Cleavage of C–C Bonds by Enzymatic Oxidation–Reduction Reactions
Guengerich, F. P., & Yoshimoto, F. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00031 · Cited by 296
Coffee Silverskin Extract: Nutritional Value, Safety and Effect on Key Biological Functions
Iriondo-DeHond, A., Rios, M. B., Herrera, T., Rodriguez-Bertos, A., Nuñez, F., San Andres, M. I., Sanchez-Fortun, S., & del Castillo, M. D. (2019) · Nutrients · doi:10.3390/nu11112693 · Cited by 56
Hardwick, R. N., Betts, C. J., Whritenour, J., Sura, R., Thamsen, M., Kaufman, E. H., & Fabre, K. (2020) · Lab on a Chip · doi:10.1039/c9lc00519f · Cited by 48
Metadata
- Venue
- CRC Press eBooks
- Publisher
- CRC Press
- Published
- 2014-10-10
- OpenAlex
- W2501169448
- Cited by
- 280
- References
- 86
- FWCI
- 32.15
- Type
- book
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.